Stock fact sheet · data as of
Liquidia Corporation (LQDA): fair value, margin of safety and Wheel Score
Healthcare · Medical - Pharmaceuticals · United States · High Growth
Is LQDA undervalued?
LQDA closed at 34.78 on 16 Oct 2026, which is 17% above the GLS average fair value of 29.69 from 7 models. 5 of them value the shares below today's price. Our screens read that as "no margin of safety": the stock is not a value candidate at this price, whatever the quality numbers say.
The 7 models disagree widely: Graham Number gives 8.78 while Graham Growth gives 66.30. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files LQDA under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for LQDA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 8.78 | -75% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 66.30 | +91% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 27.28 | -22% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 49.07 | +41% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 17.32 | -50% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 21.80 | -37% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 17.33 | -50% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -1.03 | -103% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 72.36 | +108% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - LQDA passes 6 of the nine Piotroski tests, which passes the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 1.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -28.4%, ROE -154.0%, ROA -21.0% - with debt at 4.42 times equity and a free-cash-flow yield of 1.9%. Debt of 4.42 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.
Liquidia Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 99%, Service 1% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 6 / 9 | ROIC | -28.4% |
|---|---|---|---|
| GLS Moat | 1.7 / 10 | ROE | -154.0% |
| Debt / equity | 4.42 | ROA | -21.0% |
| Free-cash-flow yield | 1.9% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 52: Fair
LQDA scores 52 out of 100 on the Wheel Score (Fair band, 50-64): a usable but unremarkable fit for the wheel strategy. The parts: Value 5/25, Health 13/20, Moat 3/15, Premium 12/20, Stability 18/20. Value (5/25) is where the points are missing.
Implied volatility is 91% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (12 of 20) because volatility this high usually comes with a reason. The option chain is deep: 198,898 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 7.1M shares a day on a market cap of $3.1B, with a beta of 0.54 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 18 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 5 / 25 | -17% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 3 / 15 | moat 1.7/10 | |
| Premium | 12 / 20 | implied volatility 91% | |
| Stability | 18 / 20 | 7.1M shares/day, $3.1B cap, beta 0.54 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 2 Nov 2026 (before the open), 17 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Pharmaceuticals
The 12 companies below are the closest to Liquidia Corporation by market cap within the Medical - Pharmaceuticals industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| RTEZ Rest Ez Inc. | 70.00 | 0.0327 | -213797% | 12No options | $4.2B |
| PBH Prestige Consumer Healthcare Inc. | 48.40 | 105.25 | +54% | 76Good | $2.3B |
| KNSA Kiniksa Pharmaceuticals International, plc | 79.94 | 46.31 | -73% | 55Fair | $6.2B |
| CORT Corcept Therapeutics Incorporated | 113.37 | 24.31 | -366% | 57Fair | $12.3B |
| HELP Helus Pharma Inc. | 11.05 | 3.18 | -248% | 28Weak | $685M |
| RPRX Royalty Pharma plc | 58.99 | 64.00 | +8% | 76Good | $26.3B |
| HITI High Tide Inc. | 2.56 | 5.54 | +54% | 45Weak | $228M |
| CTOR Citius Oncology, Inc. | 0.7460 | 0.1046 | -613% | 9No options | $69M |
| GWLL Goldenwell Biotech, Inc. | 0.6000 | 0.0007 | -87122% | 3No options | $59M |
| COSM Cosmos Health Inc. | 0.3364 | - | - | 36Weak | $34M |
| NSRX Nasus Pharma Ltd. | 3.17 | 0.0567 | -5486% | 4No options | $27M |
| SCYX SCYNEXIS, Inc. | 3.96 | - | - | 32Weak | $25M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about LQDA
Is LQDA undervalued right now?
No: at 34.78 the stock trades 17% above the GLS average fair value of 29.69 (data as of 16 Oct 2026). The margin of safety is negative.
What is the Wheel Score of LQDA and what does it mean?
LQDA scores 52 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for LQDA?
29.69 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Liquidia Corporation report earnings next?
The next earnings report is due on 2 Nov 2026 (before the open), 17 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does LQDA have listed options, and how liquid are they?
Yes. The nightly snapshot found 1,000 listed contracts with 198,898 open interest across all expiries and implied volatility of 91% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.